Janesville's BaZinga Classic Pub & Grille is organizing "Andy's Army Benefit" on April 12 to support 11-year-old Andy DeLong, who was diagnosed with acute lymphoblastic leukemia in January. The fundra ...

The allowed claims cover BioCardia's helical needle-tipped catheter technology platform, which available data supports is the safest and most efficient approach for biotherapeutic delivery to the ...

BioCardia ®, Inc . [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office ...

BioCardia (BCDA) announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery ...

The global IV therapy and vein access devices market is on a trajectory of significant growth, projected to expand from USD 28.7 billion in 2024 to an estimated USD 47.3 billion by 2034. With a ...

An 11-month-old baby born with a life-threatening hole in his heart was saved by a cutting-edge hybrid procedure performed at ...

The Embryo Transfer Catheter consists of a soft, low-friction, flexible material, which promotes optimal positioning of the embryo and at the same time, guarantees the intrauterine protection of ...

Without a port, a new intravenous (IV) needle would need to be placed each and every time you have chemo. A chemo port differs from a peripherally inserted central catheter (also known as a PICC line) ...

Varipulse is a treatment option for atrial fibrillation. Credit: Orawan Pattarawimonchai / Shutterstock. Johnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a ...

The only potential upside scenario is if APT manual mapping catheter sales are strong, but I don’t expect them to be a big needle mover. I believe APT will hit $5 million in annual sales in 2025.